Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06649877 · ClinicalTrials.gov registry record · Phase 1
MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06649877 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 16 participants.
The verdict
NCT06649877, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to MK-6194 in a healthy person's body when different injection sites are used. Researchers will compare what happens to MK-6194 in a healthy person's body when it is injected into the abdomen and when it is injected into the thigh. Researchers think that the average amount of MK-6194 in a person's body over time will be similar when injected into the thigh or abdomen. They also want to learn if it is safe to inject MK-6194 into the abdomen and thigh, and if people tolerate it.
Interventions
- BIOLOGICAL MK-6194
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2023-07-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06649877
The ClinicalTrials.gov registry entry for NCT06649877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MK-6194 is the first listed.
NCT06649877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06649877 about?
NCT06649877 is a clinical study titled "MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)". The goal of this study is to learn what happens to MK-6194 in a healthy person's body when different injection sites are used. Researchers will compare what happens to MK-6194 in a healthy person's body when it is injected into the abdomen and when it is injected into the thigh. Researchers think th...
What is the current status of trial NCT06649877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-03-20. Estimated completion is 2023-07-13.
What interventions are being tested in trial NCT06649877?
The interventions under investigation include: MK-6194 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06649877?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.